Back to Authors

Hemphill, Claude

Mayo Clinic

San Francisco General Hospital

Citations 5

Variations in Brain Death Declaration: A Worldwide Survey (P4.298)
Wahlster, Sarah , Hemphill, Claude, Wijdicks, Eelco F. M. , Patel, Pratik, Greer, David M. , Mateen, Farrah J.

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.p4.298 Get It

Variations in Brain Death Declaration: A Worldwide Survey (I10-2.002)
Wahlster, Sarah , Patel, Pratik, Hemphill, Claude, Wijdicks, Eelco F. M. , Greer, David M. , Mateen, Farrah J.

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.i10-2.002 Get It

Point-of-Care Platform Blood Biomarker Testing of Glial Fibrillary Acidic Protein versus S100 Calcium-Binding Protein B for Prediction of Traumatic Brain Injuries: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study
Okonkwo, David O. , Puffer, Ross C. , Puccio, Ava M. , Yuh, Esther L. , Yue, John K. , Korley, Frederick K. , Sun, Xiaoying, Taylor, Sabrina R. , Jain, Sonia , Manley, Geoffrey T. , Boase, Kim, Bullock, Ross, Crawford, Karen , Dikmen, Sureyya, Duhaime, Ann-Christine, Ellenbogen, Richard G. , Feeser, V. Ramana, Ferguson, Adam R. , González, Luis, Gopinath, Shankar P. , Gullapalli, Rao P. , Hemphill, Claude, Hotz, Gillian , Kramer, Joel H. , Kreitzer, Natalie , Levin, Harvey S. , Machamer, Joan , Madden, Christopher , McAllister, Thomas W. , McCrea, Michael , Merchant, Randall E., Noël, Florence, Palacios, Eva , Perl, Daniel P. , Rabinowitz, Miri, Robertson, Claudia S. , Satris, Gabriella, Seabury, Seth A., Sherer, Mark , Stein, Murray , Temkin, Nancy, Toga, Arthur W. , Valadka, Alex B. , Vassar, Mary J. , Vespa, Paul , Zafonte, Ross , Diaz‐Arrastia, Ramon , Wang, Kevin , Mukherjee, Pratik , Markowitz, Amy J. , Adeoye, Opeolu M , Badjatia, Neeraj , Bodien, Yelena G. , Chesnut, Randall Matthew , Corrigan, John D. , Foreman, Brandon , Gardner, Raquel C. , Gaudette, Étienne , Giacino, Joseph T. , Goldman, Dana P. , Lindsell, Christopher J. , Martin, Alastair J. , Nelson, Lindsay D. , Ngwenya, Laura Benjamin , Rosand, Jonathan M. , Sander, Angelle M. , Schnyer, David M. , Stein, Murray B.

Journal of Neurotrauma | August 28, 2020 | Volume: 37 | Issue: 23 | Pages: 2460-2467

10.1089/neu.2020.7140 Get It

Glial fibrillary acidic protein (GFAP) is cleared by the Food and Drug Administration (FDA) to determine need for head computed tomography (CT) within 12 h after mild traumatic brain injury (TBI) (Glasgow Coma Score [GCS] 13–15); S100 calcium-binding protein B (S100B) serves this function in Europe. This phase 1 biomarker cohort analysis of the multi-center, observational Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study compares GFAP's diagnostic performance, measured on a rapid point-of-care platform, against protein S100B to predict intracranial abnormalities on CT within 24 h post-injury across the spectrum of TBI (GCS 3–15). Head CT scan performed in TBI subjects and blood was collected for all consenting subjects presenting to 18 United States level 1 trauma centers. Plasma was analyzed on a point-of-care device prototype assay for GFAP and serum was analyzed for S100B. In 1359 patients with TBI (GCS 3–15), mean (standard deviation [SD]) age = 40.1 (17.0) years; 68% were male. Plasma GFAP levels were significantly higher in CT+ TBI subjects (median = 1358 pg/mL, interquartile range [IQR]: 472–3803) than in CT- TBI subjects (median = 116 pg/mL, IQR: 26–397) or orthopedic trauma controls ( n = 122; median = 13 pg/mL, IQR: 7–20), p < 0.001. Serum S100B levels were likewise higher in CT+ TBI subjects (median = 0.17 μg/L, IQR: 0.09–0.38) than in CT- TBI subjects (median = 0.10 μg/L, IQR: 0.06–0.18), p < 0.001. Receiver operating characteristic curves were generated for prediction of intracranial injury on admission CT scan; area under the curve (AUC) for GFAP was significantly higher than for S100B in the same cohort (GFAP AUC – 0.85, 95% confidence interval [CI] 0.83–0.87; S100B AUC – 0.67, 95% CI 0.64-0.70; p < 0.001). GFAP, measured on a point-of-care platform prototype assay, has high discriminative ability to predict intracranial abnormalities on CT scan in patients with TBI across the full injury spectrum of GCS 3–15 through 24 h post-injury. GFAP substantially outperforms S100B.
Expertise Matters
Manno, Edward M., Freeman, William D. , Livesay, Sarah , Geocadin, Romergryko G. , Torbey, Michel , Hemphill, Claude, Nyquist, Paul , Freeman, William D

Critical Care Medicine | October 15, 2016 | Volume: 44 | Issue: 11 | Pages: e1147-e1148

10.1097/ccm.0000000000001993 Get It